In vitro, PD-L1 antibody had no role in cancer killing (see ARAC vs. iPLK1-NP; Fig. 4d) or enhancing the delivery (as all nanoparticles were taken up by cells within 3 days regardless of PD-L1 antibody loading). This evidence concerns the gene CD274 and cancer.